Novartis has reported a 28.5% reduced risk of breast cancer recurrence in an updated analysis from the Phase III NATALEE trial of Kisqali (ribociclib), when combined with endocrine therapy.

By Georg Szalai Global Business Editor Bessi is charged by the nine member companies of The Creatives with “establishing a unique integrated structure for the international alliance and ...

Bessi, who in February left his CEO post at Newen Studios, has been entrusted by the nine member companies of The Creatives with setting up a “unique integrated structure for the alliance and ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...

Creatives — artists, filmmakers, and writers — tend to be right-brained people. They can draft new worlds out of thin air and imagine things that never were. But, ask them to draw up an ...

Whether you're building a top-of-the-line gaming PC, or a lean machine for a creative workload, you're going to need a good graphics card. Our top picks of the best GPUs to get right now have been ...